Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KELLEY WILSON

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1932398757
CMS profile
224261
Location
TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$389.28

8 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $389.28 8

By paying entity

PY2022 · entire year · sorted by reported total

Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KELLEY WILSON

NPI 1932398757 · CMS profile ID 224261

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1932398757?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KELLEY WILSON, NPI 1932398757, CMS profile ID 224261. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1932398757?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). KELLEY WILSON, NPI 1932398757, CMS profile ID 224261. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1932398757?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
KELLEY WILSON, NPI 1932398757, CMS profile ID 224261, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1932398757?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

8 matching records · $389.28 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 8 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–8 of 8.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GENZYME CORPORATION $20.3411/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938955291 CMS
IDORSIA PHARMACEUTICALS US INC $125.0011/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951474987 CMS
Janssen Biotech, Inc. $23.2610/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885758267 CMS
Corium, LLC $122.4009/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 924876759 CMS
Janssen Biotech, Inc. $17.9409/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885758261 CMS
Journey Medical Corporation $15.8208/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 924778721 CMS
Lilly USA, LLC $28.5507/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918158195 CMS
Regeneron Healthcare Solutions, Inc. $35.9706/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927483773 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,773.33 11
PY2020 $65.09 3
PY2021 $268.69 10
PY2022 $389.28 8
PY2023 $1,820.04 73
PY2024 $683.61 29
PY2025 $717.46 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,698,890.20 111
PY2024 Principal investigator $3,248,583.50 103
PY2023 Recipient $1,039.86 1
PY2023 Principal investigator $1,084,081.62 189
PY2022 Recipient $1,428.00 1
PY2022 Principal investigator $532,395.28 190
PY2021 Recipient $1,678.03 1
PY2021 Principal investigator $1,711,588.07 233
PY2020 Principal investigator $1,081,919.61 115
PY2019 Principal investigator $698,002.09 160

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

111 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genentech, Inc. $887.00 12/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211568886
Principal investigator 1 H. Lundbeck A S $2,010.00 12/19/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251778639
Principal investigator 1 Genentech, Inc. $4,504.00 12/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211568829
Principal investigator 1 H. Lundbeck A S $350.00 12/11/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251778334
Principal investigator 1 Genentech, Inc. $500.00 12/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211568769
Principal investigator 1 Genentech, Inc. $63,115.00 12/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211568938
Principal investigator 1 H. Lundbeck A S $4,964.00 12/04/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251778064
Principal investigator 1 H. Lundbeck A S $3,723.00 12/04/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251778069
Principal investigator 1 Janssen Research & Development, LLC $16,204.00 11/24/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175429597
Principal investigator 1 Janssen Research & Development, LLC $23,120.00 11/24/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175429603
Principal investigator 1 Janssen Research & Development, LLC $6,325.00 11/24/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175429634
Principal investigator 1 Janssen Research & Development, LLC $8,102.00 11/24/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175429848
Principal investigator 1 Janssen Research & Development, LLC $97.00 11/21/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175429749
Principal investigator 1 Janssen Research & Development, LLC $755.00 11/21/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175429807
Principal investigator 1 H. Lundbeck A S $960.00 11/14/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251777201
Principal investigator 1 Eli Lilly and Company $143,976.00 11/12/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF BRENIPATIDE COMPARED WITH PLACEBO FOR THE TREATMENT OF ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE ALCOHOL USE DISORDER (RENEW-ALC-1) No dispute reported 06/30/2026 1187885402
Principal investigator 1 Eli Lilly and Company $27,694.28 11/12/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF BRENIPATIDE COMPARED WITH PLACEBO FOR THE TREATMENT OF ADULT PARTICIPANTS WITH ALCOHOL USE DISORDER (RENEW-ALC-2) No dispute reported 06/30/2026 1187886708
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,397.53 11/10/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment No dispute reported 06/30/2026 1242365935
Principal investigator 1 H. Lundbeck A S $3,506.00 11/07/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251776660
Principal investigator 1 H. Lundbeck A S $2,706.00 11/07/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251776664
Principal investigator 1 Janssen Research & Development, LLC $1,250.00 10/30/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175429726
Principal investigator 1 Janssen Research & Development, LLC $600.00 10/30/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175429836
Principal investigator 1 Janssen Research & Development, LLC $1,200.00 10/23/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175429791
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,141.80 10/13/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment No dispute reported 06/30/2026 1242363731
Principal investigator 1 Janssen Research & Development, LLC $12,650.00 10/13/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175429553
Principal investigator 1 Janssen Research & Development, LLC $6,913.00 10/13/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175429686
Principal investigator 1 Janssen Research & Development, LLC $223.00 10/13/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175429712
Principal investigator 1 Janssen Research & Development, LLC $12,488.00 10/13/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175429738
Principal investigator 1 Janssen Research & Development, LLC $223.00 10/13/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175429784
Principal investigator 1 Janssen Research & Development, LLC $11,373.00 10/13/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175429802
Principal investigator 1 Janssen Research & Development, LLC $669.00 10/13/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175429818
Principal investigator 1 Janssen Research & Development, LLC $26,537.00 10/13/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175429831
Principal investigator 1 Janssen Research & Development, LLC $223.00 10/13/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175429842
Principal investigator 1 Janssen Research & Development, LLC $5,352.00 10/13/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175429872
Principal investigator 1 Janssen Research & Development, LLC $6,325.00 10/13/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175429879
Principal investigator 1 Eli Lilly and Company $572.75 10/08/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187887080
Principal investigator 1 Janssen Research & Development, LLC $12,835.00 09/29/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175429778
Principal investigator 1 Janssen Research & Development, LLC $1,510.00 09/29/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175429825
Principal investigator 1 Janssen Research & Development, LLC $755.00 09/29/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175429854
Principal investigator 1 Janssen Research & Development, LLC $52,020.00 09/26/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175429617
Principal investigator 1 Janssen Research & Development, LLC $755.00 09/26/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175429694
Principal investigator 1 Janssen Research & Development, LLC $34,680.00 09/26/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175429734
Principal investigator 1 Janssen Research & Development, LLC $109,820.00 09/26/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175429742
Principal investigator 1 Janssen Research & Development, LLC $8,102.00 09/26/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175429766
Principal investigator 1 Janssen Research & Development, LLC $4,530.00 09/26/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175429773
Principal investigator 1 Janssen Research & Development, LLC $6,325.00 09/26/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175429859
Principal investigator 1 Genentech, Inc. $1,084.00 09/23/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567011
Principal investigator 1 Genentech, Inc. $887.00 09/23/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567135
Principal investigator 1 Genentech, Inc. $6,102.00 09/23/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567335
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,797.35 09/08/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment No dispute reported 06/30/2026 1242358620
Principal investigator 1 Genentech, Inc. $1,567.00 09/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567412
Principal investigator 1 Janssen Research & Development, LLC $1,200.00 09/01/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175429812
Principal investigator 1 Genentech, Inc. $6,935.00 08/26/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567122
Principal investigator 1 Genentech, Inc. $3,441.00 08/14/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566921
Principal investigator 1 H. Lundbeck A S $11,481.00 08/14/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251773566
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,141.80 08/11/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment No dispute reported 06/30/2026 1242356900
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,737.23 08/11/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment No dispute reported 06/30/2026 1242356902
Principal investigator 1 Janssen Research & Development, LLC $1,200.00 08/11/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175429680
Principal investigator 1 Janssen Research & Development, LLC $28,900.00 08/11/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175429797
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,041.18 08/04/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment No dispute reported 06/30/2026 1242355702
Principal investigator 1 Janssen Research & Development, LLC $1,250.00 08/04/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175429646
Principal investigator 1 Janssen Research & Development, LLC $1,510.00 08/04/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175429656
Principal investigator 1 Janssen Research & Development, LLC $1,200.00 08/04/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175429700
Principal investigator 1 Janssen Research & Development, LLC $755.00 08/04/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175429706
Principal investigator 1 Janssen Research & Development, LLC $223.00 07/25/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175429548
Principal investigator 1 Janssen Research & Development, LLC $97.00 07/25/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175429623
Principal investigator 1 Janssen Research & Development, LLC $6,325.00 07/25/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175429866
Principal investigator 1 Janssen Research & Development, LLC $8,102.00 07/25/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175429885
Principal investigator 1 Eli Lilly and Company $18.87 07/24/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) No dispute reported 06/30/2026 1187885568
Principal investigator 1 H. Lundbeck A S $3,651.00 07/10/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251772050
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $12,891.38 07/07/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment No dispute reported 06/30/2026 1242352508
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $350.00 06/18/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment No dispute reported 06/30/2026 1242351072
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 06/16/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175429720
Principal investigator 1 Janssen Research & Development, LLC $11,560.00 06/13/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175429760
Principal investigator 1 H. Lundbeck A S $2,010.00 06/05/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251770763
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $730.75 06/03/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment No dispute reported 06/30/2026 1242348700
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $30,875.00 06/02/2025 Non-covered Recipient Entity
K2 Medical Research
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease Dementia No dispute reported 06/30/2026 1235996395
Principal investigator 1 Janssen Research & Development, LLC $1,750.00 06/02/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia an No dispute reported 06/30/2026 1175429670
Principal investigator 1 Janssen Research & Development, LLC $5,550.00 05/29/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia an No dispute reported 06/30/2026 1175429611
Principal investigator 1 Eli Lilly and Company $7.56 05/15/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH - TAMPA
A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) No dispute reported 06/30/2026 1187883952
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,996.92 05/11/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment No dispute reported 06/30/2026 1242347406
Principal investigator 1 Janssen Research & Development, LLC $85,632.00 05/05/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175429900
Principal investigator 1 H. Lundbeck A S $2,010.00 04/28/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251769861
Principal investigator 1 Janssen Research & Development, LLC $15,702.00 04/28/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia an No dispute reported 06/30/2026 1175429893
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $442.87 04/23/2025 Non-covered Recipient Entity
K2 Medical Research
A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) No dispute reported 06/30/2026 1235996399
Principal investigator 1 H. Lundbeck A S $3,651.00 04/22/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251769776
Principal investigator 1 Janssen Research & Development, LLC $25,645.00 04/21/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175429630
Principal investigator 1 Janssen Research & Development, LLC $15,855.00 04/21/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175429641
Principal investigator 1 Janssen Research & Development, LLC $10,927.00 04/21/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175429675
Principal investigator 1 Janssen Research & Development, LLC $368,296.00 04/21/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175429755
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $24,817.64 04/09/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment No dispute reported 06/30/2026 1242340862
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $300.00 04/04/2025 Non-covered Recipient Entity
Advarra
A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) No dispute reported 06/30/2026 1235999219
Principal investigator 1 H. Lundbeck A S $960.00 03/25/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251769028
Principal investigator 1 Janssen Research & Development, LLC $1,250.00 03/17/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia an No dispute reported 06/30/2026 1175429651
Principal investigator 1 H. Lundbeck A S $2,706.00 03/11/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251768599
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $11,514.44 03/07/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment No dispute reported 06/30/2026 1242334800
Principal investigator 1 Eli Lilly and Company $223.77 03/05/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A PHASE 2, DOUBLE-BLIND, PROOF OF CONCEPT STUDY TO EVALUATE MAZDUTIDE COMPARED WITH PLACEBO IN PARTICIPANTS WITH ALCOHOL USE DISORDER No dispute reported 06/30/2026 1187885556
Principal investigator 1 H. Lundbeck A S $2,706.00 03/04/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251768021
Principal investigator 1 H. Lundbeck A S $10,000.00 02/25/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251767637
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $67,438.00 02/18/2025 Non-covered Recipient Entity
K2 Medical Research
A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) No dispute reported 06/30/2026 1235996397
Principal investigator 1 Eli Lilly and Company $746,798.00 02/18/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187886700
Principal investigator 1 H. Lundbeck A S $3,506.00 02/18/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251767441
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $75,730.00 02/14/2025 Non-covered Recipient Entity
K2 Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Relapse Prevention Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease No dispute reported 06/30/2026 1235996393
Principal investigator 1 Eli Lilly and Company $5,773.28 02/10/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187873537
Principal investigator 1 H. Lundbeck A S $7,157.00 02/05/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251767032
Principal investigator 1 Roche Diagnostics Operations, Inc. $1,815.80 02/04/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
RD006263 No dispute reported 06/30/2026 1186331397
Principal investigator 1 Janssen Research & Development, LLC $600.00 02/03/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175429663
Principal investigator 1 H. Lundbeck A S $3,594.00 01/29/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251766785
Principal investigator 1 Eli Lilly and Company $372,022.00 01/13/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) No dispute reported 06/30/2026 1187885548
Principal investigator 1 H. Lundbeck A S $7,887.00 01/07/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251766284
Principal investigator 1 H. Lundbeck A S $3,594.00 01/07/2025 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251766287